BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 16417400)

  • 1. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
    Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
    Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings.
    Lubezky N; Metser U; Geva R; Nakache R; Shmueli E; Klausner JM; Even-Sapir E; Figer A; Ben-Haim M
    J Gastrointest Surg; 2007 Apr; 11(4):472-8. PubMed ID: 17436132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.
    Seyal AR; Parekh K; Arslanoglu A; Gonzalez-Guindalini FD; Tochetto SM; Velichko YS; Yaghmai V
    Abdom Imaging; 2015 Oct; 40(8):3043-51. PubMed ID: 26353898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
    Mertens J; De Bruyne S; Van Damme N; Smeets P; Ceelen W; Troisi R; Laurent S; Geboes K; Peeters M; Goethals I; Van de Wiele C
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1214-22. PubMed ID: 23636802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Nielsen D; Jensen BV; Hendel HW
    J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases.
    Revheim ME; Haugvik SP; Johnsrud K; Mathisen Ø; Fjeld JG; Skretting A
    Acta Radiol; 2015 Apr; 56(4):397-403. PubMed ID: 24682406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response.
    Tan MC; Linehan DC; Hawkins WG; Siegel BA; Strasberg SM
    J Gastrointest Surg; 2007 Sep; 11(9):1112-9. PubMed ID: 17623263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
    De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
    Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
    Skougaard K; Johannesen HH; Nielsen D; Schou JV; Jensen BV; Høgdall EV; Hendel HW
    Cancer Med; 2014 Oct; 3(5):1294-301. PubMed ID: 24941936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
    Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
    Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial.
    Metser U; Halankar J; Langer D; Mohan R; Hussey D; Hadas M; Tamir S
    Ann Nucl Med; 2017 Feb; 31(2):153-162. PubMed ID: 27848159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early
    Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
    Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.